Health Law & Business News

Second Generic Drugmaker Settles U.S. Price-Fixing Charges

Dec. 3, 2019, 9:45 PM

Rising Pharmaceuticals Inc. agreed to pay more than $3 million to settle U.S. charges that it conspired to fix prices for a hypertension medicine, the second company to resolve a long-running investigation of the generic-drug industry.

Rising conspired with a competing drug manufacturer from 2014 to 2015 to fix prices for Benazepril HCTZ, the Justice Department said in a statement Tuesday.

The company is the second to settle a five-year criminal investigation by the Justice Department’s antitrust division into allegations that generic pharmaceutical companies colluded to raise prices.

The probe has targeted the biggest names in the industry, including Teva...

To read the full article log in. To learn more about a subscription click here.